1887

Abstract

Epstein–Barr virus (EBV) establishes a life-long latency in memory B cells, whereas plasma cell differentiation is linked to EBV lytic reactivation from latently infected B cells. EBV lytic replication is mediated by the two immediate-early switch proteins Zta and RTA. Both plasma cell transcription factors XBP-1 and Blimp-1 have been shown to enable the triggering of EBV lytic reactivation by activating the transcription of Zta or RTA. Here we show that interferon regulatory factor 4 (IRF4), another plasma cell transcription factor that is either not expressed or expressed at a low level in EBV-positive Burkitt’s lymphoma (BL) cells, can activate the promoters of EBV Zta and RTA, but is not sufficient to elicit EBV lytic reactivation in latently infected BL cells. However, ectopic IRF4 expression can augment EBV lytic gene expression induced by anti-immunoglobulin (anti-Ig) or sodium butyrate treatment in all tested lymphoma cells, whereas IRF4 knockout in Raji cells, the only BL cell line with detectable endogenous IRF4 expression, abolishes EBV lytic gene expression induced by anti-Ig, and this is accompanied by the reduction of Blimp-1 expression, whose overexpression, in turn, can rescue EBV lytic gene expression in IRF4 knockout Raji cells. Furthermore, IRF4 knockout impairs B cell receptor (BCR) signalling activation, which is required for BCR-mediated EBV reactivation. Altogether, these results demonstrate that IRF4 facilitates EBV lytic reactivation in BL cells, which involves the regulation of Blimp-1 expression and BCR signalling pathways.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001249
2019-03-25
2019-10-15
Loading full text...

Full text loading...

References

  1. Barton E, Mandal P, Speck SH. Pathogenesis and host control of gammaherpesviruses: lessons from the mouse. Annu Rev Immunol 2011;29:351–397 [CrossRef][PubMed]
    [Google Scholar]
  2. Kallin B, Luka J, Klein G. Immunochemical characterization of Epstein-Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells. J Virol 1979;32:710–716[PubMed]
    [Google Scholar]
  3. Westphal EM, Blackstock W, Feng W, Israel B, Kenney SC. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res 2000;60:5781–5788[PubMed]
    [Google Scholar]
  4. Moser JM, Upton JW, Gray KS, Speck SH. Ex vivo stimulation of B cells latently infected with gammaherpesvirus 68 triggers reactivation from latency. J Virol 2005;79:5227–5231 [CrossRef][PubMed]
    [Google Scholar]
  5. Tovey MG, Lenoir G, Begon-Lours J. Activation of latent Epstein-Barr virus by antibody to human IgM. Nature 1978;276:270–272 [CrossRef][PubMed]
    [Google Scholar]
  6. Zur Hausen H, O'Neill FJ, Freese UK, Hecker E. Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature 1978;272:373–375 [CrossRef][PubMed]
    [Google Scholar]
  7. Lukac DM, Renne R, Kirshner JR, Ganem D. Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology 1998;252:304–312 [CrossRef][PubMed]
    [Google Scholar]
  8. Lukac DM, Kirshner JR, Ganem D. Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J Virol 1999;73:9348–9361[PubMed]
    [Google Scholar]
  9. Ragoczy T, Heston L, Miller G. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol 1998;72:7978–7984[PubMed]
    [Google Scholar]
  10. Sun R, Lin SF, Gradoville L, Yuan Y, Zhu F et al. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci USA 1998;95:10866–10871 [CrossRef][PubMed]
    [Google Scholar]
  11. Zalani S, Holley-Guthrie E, Kenney S. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci USA 1996;93:9194–9199 [CrossRef][PubMed]
    [Google Scholar]
  12. Feederle R, Kost M, Baumann M, Janz A, Drouet E et al. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 2000;19:3080–3089 [CrossRef][PubMed]
    [Google Scholar]
  13. Speck SH, Ganem D. Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe 2010;8:100–115 [CrossRef][PubMed]
    [Google Scholar]
  14. Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003;3:801–812 [CrossRef][PubMed]
    [Google Scholar]
  15. Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M. The pathogenesis of Epstein-Barr virus persistent infection. Curr Opin Virol 2013;3:227–232 [CrossRef][PubMed]
    [Google Scholar]
  16. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 2005;79:1296–1307 [CrossRef][PubMed]
    [Google Scholar]
  17. Liang X, Paden CR, Morales FM, Powers RP, Jacob J et al. Murine gamma-herpesvirus immortalization of fetal liver-derived B cells requires both the viral cyclin D homolog and latency-associated nuclear antigen. PLoS Pathog 2011;7:e1002220 [CrossRef][PubMed]
    [Google Scholar]
  18. Mittrücker HW, Matsuyama T, Grossman A, Kündig TM, Potter J et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 1997;275:540–543 [CrossRef][PubMed]
    [Google Scholar]
  19. Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi-Tsuda E et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001;412:300–307 [CrossRef][PubMed]
    [Google Scholar]
  20. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG et al. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 2003;19:607–620 [CrossRef][PubMed]
    [Google Scholar]
  21. Bhende PM, Dickerson SJ, Sun X, Feng WH, Kenney SC. X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J Virol 2007;81:7363–7370 [CrossRef][PubMed]
    [Google Scholar]
  22. Wilson SJ, Tsao EH, Webb BL, Ye H, Dalton-Griffin L et al. X box binding protein XBP-1s transactivates the Kaposi's sarcoma-associated herpesvirus (KSHV) ORF50 promoter, linking plasma cell differentiation to KSHV reactivation from latency. J Virol 2007;81:13578–13586 [CrossRef][PubMed]
    [Google Scholar]
  23. Matar CG, Rangaswamy US, Wakeman BS, Iwakoshi N, Speck SH. Murine gammaherpesvirus 68 reactivation from B cells requires IRF4 but not XBP-1. J Virol 2014;88:11600–11610 [CrossRef][PubMed]
    [Google Scholar]
  24. Yu F, Feng J, Harada JN, Chanda SK, Kenney SC et al. B cell terminal differentiation factor XBP-1 induces reactivation of Kaposi's sarcoma-associated herpesvirus. FEBS Lett 2007;581:3485–3488 [CrossRef][PubMed]
    [Google Scholar]
  25. Dalton-Griffin L, Wilson SJ, Kellam P. X-box binding protein 1 contributes to induction of the Kaposi's sarcoma-associated herpesvirus lytic cycle under hypoxic conditions. J Virol 2009;83:7202–7209 [CrossRef][PubMed]
    [Google Scholar]
  26. Siegel AM, Rangaswamy US, Napier RJ, Speck SH. Blimp-1-dependent plasma cell differentiation is required for efficient maintenance of murine gammaherpesvirus latency and antiviral antibody responses. J Virol 2010;84:674–685 [CrossRef][PubMed]
    [Google Scholar]
  27. Reusch JA, Nawandar DM, Wright KL, Kenney SC, Mertz JE. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters. J Virol 2015;89:1731–1743 [CrossRef][PubMed]
    [Google Scholar]
  28. Rangaswamy US, Speck SH. Murine gammaherpesvirus M2 protein induction of IRF4 via the NFAT pathway leads to IL-10 expression in B cells. PLoS Pathog 2014;10:e1003858 [CrossRef][PubMed]
    [Google Scholar]
  29. Forero A, McCormick KD, Jenkins FJ, Sarkar SN. Downregulation of IRF4 induces lytic reactivation of KSHV in primary effusion lymphoma cells. Virology 2014;458-459:4–4–10 [CrossRef][PubMed]
    [Google Scholar]
  30. Lee HR, Doğanay S, Chung B, Toth Z, Brulois K et al. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets expression of cellular IRF4 and the Myc gene to facilitate lytic replication. J Virol 2014;88:2183–2194 [CrossRef][PubMed]
    [Google Scholar]
  31. Tan L, Zhang C, Dematos J, Kuang L, Jung JU et al. CD95 signaling inhibits B cell receptor-mediated gammaherpesvirus replication in apoptosis-resistant B lymphoma cells. J Virol 2016;90:9782–9796 [CrossRef][PubMed]
    [Google Scholar]
  32. Vrzalikova K, Vockerodt M, Leonard S, Bell A, Wei W et al. Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood 2011;117:5907–5917 [CrossRef][PubMed]
    [Google Scholar]
  33. Sun CC, Thorley-Lawson DA. Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J Virol 2007;81:13566–13577 [CrossRef][PubMed]
    [Google Scholar]
  34. Chatila T, Ho N, Liu P, Liu S, Mosialos G et al. The Epstein-Barr virus-induced Ca2+/calmodulin-dependent kinase type IV/Gr promotes a Ca(2+)-dependent switch from latency to viral replication. J Virol 1997;71:6560–6567[PubMed]
    [Google Scholar]
  35. Brass AL, Kehrli E, Eisenbeis CF, Storb U, Singh H, Pip SH. Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1. Genes Dev 1996;10:2335–2347 [CrossRef][PubMed]
    [Google Scholar]
  36. Teng Y, Takahashi Y, Yamada M, Kurosu T, Koyama T et al. IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells. Eur J Cell Biol 2007;86:581–589 [CrossRef][PubMed]
    [Google Scholar]
  37. Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM et al. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 2006;25:225–236 [CrossRef][PubMed]
    [Google Scholar]
  38. Iwakiri D, Takada K. Phosphatidylinositol 3-kinase is a determinant of responsiveness to B cell antigen receptor-mediated Epstein-Barr virus activation. J Immunol 2004;172:1561–1566 [CrossRef][PubMed]
    [Google Scholar]
  39. Daibata M, Humphreys RE, Takada K, Sairenji T. Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata. J Immunol 1990;144:4788–4793[PubMed]
    [Google Scholar]
  40. Sciammas R, Li Y, Warmflash A, Song Y, Dinner AR et al. An incoherent regulatory network architecture that orchestrates B cell diversification in response to antigen signaling. Mol Syst Biol 2011;7:495 [CrossRef][PubMed]
    [Google Scholar]
  41. Liang X, Collins CM, Mendel JB, Iwakoshi NN, Speck SH. Gammaherpesvirus-driven plasma cell differentiation regulates virus reactivation from latently infected B lymphocytes. PLoS Pathog 2009;5:e1000677 [CrossRef][PubMed]
    [Google Scholar]
  42. Lai IY, Farrell PJ, Kellam P. X-box binding protein 1 induces the expression of the lytic cycle transactivator of Kaposi's sarcoma-associated herpesvirus but not Epstein-Barr virus in co-infected primary effusion lymphoma. J Gen Virol 2011;92:421–431 [CrossRef][PubMed]
    [Google Scholar]
  43. Klein U, Casola S, Cattoretti G, Shen Q, Lia M et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 2006;7:773–782 [CrossRef][PubMed]
    [Google Scholar]
  44. Correia S, Palser A, Elgueta Karstegl C, Middeldorp JM, Ramayanti O et al. Natural variation of Epstein-Barr virus genes, proteins and primary microRNA. J Virol 2017;91: [CrossRef][PubMed]
    [Google Scholar]
  45. Bristol JA, Djavadian R, Albright ER, Coleman CB, Ohashi M et al. A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection. PLoS Pathog 2018;14:e1007179 [CrossRef][PubMed]
    [Google Scholar]
  46. Binné UK, Amon W, Farrell PJ. Promoter sequences required for reactivation of Epstein-Barr virus from latency. J Virol 2002;76:10282–10289 [CrossRef][PubMed]
    [Google Scholar]
  47. Mellinghoff I, Daibata M, Humphreys RE, Mulder C, Takada K et al. Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation. Virology 1991;185:922–928 [CrossRef][PubMed]
    [Google Scholar]
  48. Banerjee S, Lu J, Cai Q, Saha A, Jha HC et al. The EBV latent antigen 3C inhibits apoptosis through targeted regulation of interferon regulatory factors 4 and 8. PLoS Pathog 2013;9:e1003314 [CrossRef][PubMed]
    [Google Scholar]
  49. O'Flaherty BM, Soni T, Wakeman BS, Speck SH. The murine gammaherpesvirus immediate-early Rta synergizes with IRF4, targeting expression of the viral M1 superantigen to plasma cells. PLoS Pathog 2014;10:e1004302 [CrossRef][PubMed]
    [Google Scholar]
  50. Xi X, Persson LM, O'Brien MW, Mohr I, Wilson AC. Cooperation between viral interferon regulatory factor 4 and RTA to activate a subset of Kaposi's sarcoma-associated herpesvirus lytic promoters. J Virol 2012;86:1021–1033 [CrossRef][PubMed]
    [Google Scholar]
  51. Shaffer AL, Emre NC, Romesser PB, Staudt LM. IRF4: immunity. malignancy! therapy?. Clin Cancer Res 2009;15:2954–2961 [CrossRef][PubMed]
    [Google Scholar]
  52. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28–40[PubMed]
    [Google Scholar]
  53. Majumder S, Zhou LZ, Chaturvedi P, Babcock G, Aras S et al. p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. J Immunol 1998;161:4736–4744[PubMed]
    [Google Scholar]
  54. Xu D, Zhao L, del Valle L, Miklossy J, Zhang L. Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. J Virol 2008;82:6251–6258 [CrossRef][PubMed]
    [Google Scholar]
  55. Shaffer AL, Rosenwald A, Hurt EM, Giltnane JM, Lam LT et al. Signatures of the immune response. Immunity 2001;15:375–385 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001249
Loading
/content/journal/jgv/10.1099/jgv.0.001249
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error